All News Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Delayed Nasdaq Other stock markets 12:27:46 16/05/2024 am IST			5-day change	1st Jan Change
1.428 ^USD	-1.54%		-7.90%	-47.13%

22/04	Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	MT
22/04	Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enlivex Therapeutics : Report of Periodic or Interim Report	01/05	PU
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events	29/04	GL
Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	22/04	MT
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	22/04	GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	22/04	AQ
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	22/04	CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	16/04	MT
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	16/04	GL
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	16/04	CI
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating	12/04	MT
Sector Update: Health Care Stocks Softer Late Afternoon	12/04	MT
Sector Update: Health Care	12/04	MT
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis	12/04	GL
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study	11/04	MT
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis	11/04	GL
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis	11/04	CI
Enlivex Therapeutics : Notes to Consolidated Financial Statements - Form 6-K	30/03	PU
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.	30/03	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

All News

Filters